Key Influencer in the Intestinal Pseudo-Obstruction Treatment Market 2025: Parkinson's Disease-Associated Gastrointestinal Issues Boost Intestinal Pseudo-Obstruction Treatment Market Driver

"Which drivers are expected to have the greatest impact on the over the intestinal pseudo-obstruction treatment market's growth?
The escalating instances of Parkinson's disease are set to spur the advancement of the intestinal pseudo-obstruction treatment space. Parkinson's disease is a neurodegenerative disorder predominantly impacting the dopamine-producing neurons situated in the substantia nigra - a specific part of the brain. With Parkinson's disease, there's a heightened occurrence of IPO due to its effect on the enteric nervous system. This causes gastrointestinal dysmotility, leading to megacolon or intestinal obstruction, including acute colonic pseudo-obstruction. As reported by the Parkinson's Foundation in December 2022, around 90,000 Americans are diagnosed with Parkinson's disease annually - a 50% hike from the previous estimation of 60,000 diagnoses. Furthermore, projections suggest that by 2030, Parkinson's disease will afflict 1.2 million people worldwide. Consequently, the surge in Parkinson's disease propels the growth of the intestinal pseudo-obstruction treatment arena. The intestinal pseudo-obstruction treatment market is observing growth due to the upward trend in cancer cases. Cancer, defined by the uncontrolled growth and spread of certain body cells, is also a significant market driver. The rise in sedentary living, unhealthy diets, and tobacco consumption amplifies the risk of cancer. In the context of intestinal pseudo-obstruction, cancer treatment primarily focuses on treating the underlying cancer, which can relieve or eradicate the gastrointestinal symptoms linked to pseudo-obstruction. For example, as per the Macmillan Cancer Support's report in October 2022, about 3 million people in the UK have cancer, with projections suggesting it will escalate to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the rise in the number of cancer patients is spearheading the growth of the intestinal pseudo-obstruction treatment market.

Get Your Intestinal Pseudo-Obstruction Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/intestinal-pseudo-obstruction-treatment-global-market-report

What is the future CAGR of the intestinal pseudo-obstruction treatment market, and how will it impact industry expansion?
In recent times, the market size for the treatment of intestinal pseudo-obstruction has seen significant growth. It is projected to rise from $23.46 billion in 2024 to $24.87 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.0%. The substantial growth in the historical period can be linked to the increased recognition and diagnosis, improvements in medical imaging technology, advancements in testing for gastrointestinal motility, along with expanded global access to healthcare.

The market size for treatment of intestinal pseudo-obstruction is predicted to experience substantial expansion in the upcoming years. The market is anticipated to reach a value of $30.9 billion in 2029, growing at a compound annual growth rate (CAGR) of 5.6%. The growth expected in the forecasted period is largely due to elements like drug research and development, telemedicine and remote patient monitoring, patient education and support, and reimbursement policies. Key trends in the projected period involve advanced gastrointestinal motility testing, immunomodulatory therapies, nutritional interventions, data analytics and artificial intelligence.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12995&type=smp

Which key market segments comprise the intestinal pseudo-obstruction treatment market and drive its revenue growth?
The intestinal pseudo-obstruction treatment market covered in this report is segmented -

1) By Drug Class: Antibiotics, Antidepressants, Antidiarrheals
2) By Treatment: Medication, Surgery, Diet, Decompression, Other Treatments
3) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations
4) By Diagnosis: Physical Examination, Biopsy, Blood Test, Gastric Emptying Tests, Imaging Tests, Other Diagnosis
5) By End User: Clinic, Hospitals, Other End Users

Subsegments:
1) By Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics
2) By Antidepressants: Tricyclic Antidepressants (TCAs), Selective Serotonin Reuptake Inhibitors (SSRIs)
3) By Antidiarrheals: Loperamide, Bismuth Subsalicylate

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12995

What regions are at the forefront of intestinal pseudo-obstruction treatment market expansion?
North America was the largest region in the intestinal pseudo-obstruction treatment market in 2024. The regions covered in intestinal pseudo-obstruction (IPO) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the leading players fueling growth in the intestinal pseudo-obstruction treatment market?
Major companies operating in the intestinal pseudo-obstruction treatment market are F. Hoffmann-La Roche AG, Merck Sharp & Dohme Corp, Bayer AG, Sanofi S.A., AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Amgen PLC, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Mylan N.V., Biogen Inc., Penn Medicine, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Inc., Dr. Reddy's Laboratories Ltd., Allergan PLC, Torrent Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Melinta Therapeutics LLC, Tetraphase Pharmaceuticals Inc., Callisto Pharmaceuticals Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=12995&type=smp

What Is Covered In The Intestinal Pseudo-Obstruction Treatment Global Market Report?

•Market Size Forecast: Examine the intestinal pseudo-obstruction treatment market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the intestinal pseudo-obstruction treatment market for a structured understanding.
•Key Players Overview: Analyze major players in the intestinal pseudo-obstruction treatment market, including their market value, share, and competitive positioning.

•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the intestinal pseudo-obstruction treatment market.
•Segment Contributions: Evaluate how different segments drive overall growth in the intestinal pseudo-obstruction treatment market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the intestinal pseudo-obstruction treatment market.
•Industry Challenges: Identify potential risks and obstacles affecting the intestinal pseudo-obstruction treatment market.
•Competitive Landscape: Review strategic developments in the intestinal pseudo-obstruction treatment market, including expansions, agreements, and new product launches.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.